>
Bicycle Therapeutics logo

BCYC - Bicycle Therapeutics Share Price

$31.2 0.8  2.6%

Last Trade - 22/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £503.9m
Enterprise Value £416.7m
Revenue £7.46m
Position in Universe 3173rd / 6852
Bullish
Bearish
Unlock BCYC Revenue
Momentum
Relative Strength (%)
1m +10.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -8.43%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 2.06 7.14 13.8 10.4 9.65 7.75
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BicycleTherapeutics PLC (ADR) revenues decreased 25% to $10.4M.Net loss increased 67% to $51M. Revenues reflect a decreasein demand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsGeneral and administrative - Balancing increase of 52% to$19.4M (expense), Research and development - Balancing vaincrease of 26% to $30.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BCYC
Graphical History

Revenue

BCYC Revenue Unlock BCYC Revenue

Net Income

BCYC Net Income Unlock BCYC Revenue

Normalised EPS

BCYC Normalised EPS Unlock BCYC Revenue

PE Ratio Range

BCYC PE Ratio Range Unlock BCYC Revenue

Dividend Yield Range

BCYC Dividend Yield Range Unlock BCYC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BCYC EPS Forecasts Unlock BCYC Revenue
Profile Summary

Bicycle Therapeutics PLC, formerly Bicycle Therapeutics Limited, is a clinical-stage biopharmaceutical company. The Company is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The Company is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The Company is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated October 27, 2017
Public Since May 23, 2019
No. of Shareholders: 73
No. of Employees: 87
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 23,090,382
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BCYC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BCYC
Upcoming Events for BCYC
Thursday 24th June, 2021
Bicycle Therapeutics PLC Ordinary Shareholders Meeting
Monday 28th June, 2021
Bicycle Therapeutics PLC Annual Shareholders Meeting
Frequently Asked Questions for Bicycle Therapeutics
What is the Bicycle Therapeutics share price?

As of 22/04/21, shares in Bicycle Therapeutics are trading at $31.2, giving the company a market capitalisation of £503.9m. This share price information is delayed by 15 minutes.

How has the Bicycle Therapeutics share price performed this year?

Shares in Bicycle Therapeutics are currently trading at $31.2 and the price has moved by 0.101k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bicycle Therapeutics price has moved by 36.02% over the past year.

What are the analyst and broker recommendations for Bicycle Therapeutics?

There are no analysts currently covering Bicycle Therapeutics.

When will Bicycle Therapeutics next release its financial results?

Bicycle Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Bicycle Therapeutics dividend yield?

Bicycle Therapeutics does not currently pay a dividend.

Does Bicycle Therapeutics pay a dividend?

Bicycle Therapeutics does not currently pay a dividend.

When does Bicycle Therapeutics next pay dividends?

Bicycle Therapeutics does not currently pay a dividend.

How do I buy Bicycle Therapeutics shares?

To buy shares in Bicycle Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bicycle Therapeutics?

Shares in Bicycle Therapeutics are currently trading at $31.2, giving the company a market capitalisation of £503.9m.

Where are Bicycle Therapeutics shares listed? Where are Bicycle Therapeutics shares listed?

Here are the trading details for Bicycle Therapeutics:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BCYC
What kind of share is Bicycle Therapeutics?

Based on an overall assessment of its quality, value and momentum, Bicycle Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bicycle Therapeutics share price forecast 2021?

Shares in Bicycle Therapeutics are currently priced at $31.2. At that level they are trading at 26.84% discount to the analyst consensus target price of 0.00.

Analysts covering Bicycle Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -3.012 for the next financial year.

How can I tell whether the Bicycle Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bicycle Therapeutics. Over the past six months, the relative strength of its shares against the market has been 31.67%. At the current price of $31.2, shares in Bicycle Therapeutics are trading at 41.11% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bicycle Therapeutics PE Ratio?

We were not able to find PE ratio data for Bicycle Therapeutics.

Who are the key directors of Bicycle Therapeutics?

We were unable to find the directors for Bicycle Therapeutics.

Who are the major shareholders of Bicycle Therapeutics?

Here are the top five shareholders of Bicycle Therapeutics based on the size of their shareholding:

Tybourne Capital Management (HK) Limited Hedge Fund
Percentage owned: 9.28% (1.96m shares)
SV Health Investors, LLC Venture Capital
Percentage owned: 9.08% (1.92m shares)
Ridgeback Capital Management, L.P. Hedge Fund
Percentage owned: 8.83% (1.86m shares)
Novartis AG Corporation
Percentage owned: 8.38% (1.77m shares)
Point72 Asset Management, L.P. Hedge Fund
Percentage owned: 6.81% (1.44m shares)
Similar to BCYC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.